Baylor College of Medicine: Promising Results for Hyperlipidemia Treatment Reduces Risk of Cardiovascular Events
May 29, 2024
May 29, 2024
HOUSTON, Texas, May 29 (TNSres) -- The Baylor College of Medicine issued the following news:
Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia - elevations of triglycerides and cholesterol.
The results, published in the latest edition of the New England Journal of Medicine, demonstrate how the drug plozasiran works by targeting ApoC3, which is a key regulator of the . . .
Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia - elevations of triglycerides and cholesterol.
The results, published in the latest edition of the New England Journal of Medicine, demonstrate how the drug plozasiran works by targeting ApoC3, which is a key regulator of the . . .